PE20060102A1 - Pequenas moleculas para el tratamiento de hipercolesterolemia y enfermedades relacionadas - Google Patents
Pequenas moleculas para el tratamiento de hipercolesterolemia y enfermedades relacionadasInfo
- Publication number
- PE20060102A1 PE20060102A1 PE2005000656A PE2005000656A PE20060102A1 PE 20060102 A1 PE20060102 A1 PE 20060102A1 PE 2005000656 A PE2005000656 A PE 2005000656A PE 2005000656 A PE2005000656 A PE 2005000656A PE 20060102 A1 PE20060102 A1 PE 20060102A1
- Authority
- PE
- Peru
- Prior art keywords
- amino
- acid
- guanidin
- same
- hypercholesterolemia
- Prior art date
Links
- 208000035150 Hypercholesterolemia Diseases 0.000 title abstract 2
- 201000010099 disease Diseases 0.000 title 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 title 1
- 150000003384 small molecules Chemical class 0.000 title 1
- 150000001413 amino acids Chemical class 0.000 abstract 4
- -1 AMINO Chemical class 0.000 abstract 3
- KXDAEFPNCMNJSK-UHFFFAOYSA-N Benzamide Chemical compound NC(=O)C1=CC=CC=C1 KXDAEFPNCMNJSK-UHFFFAOYSA-N 0.000 abstract 2
- FERIUCNNQQJTOY-UHFFFAOYSA-N Butyric acid Chemical compound CCCC(O)=O FERIUCNNQQJTOY-UHFFFAOYSA-N 0.000 abstract 2
- 239000002253 acid Substances 0.000 abstract 2
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 abstract 2
- IDCPFAYURAQKDZ-UHFFFAOYSA-N 1-nitroguanidine Chemical compound NC(=N)N[N+]([O-])=O IDCPFAYURAQKDZ-UHFFFAOYSA-N 0.000 abstract 1
- KJUGUADJHNHALS-UHFFFAOYSA-N 1H-tetrazole Chemical compound C=1N=NNN=1 KJUGUADJHNHALS-UHFFFAOYSA-N 0.000 abstract 1
- 102000005666 Apolipoprotein A-I Human genes 0.000 abstract 1
- 108010059886 Apolipoprotein A-I Proteins 0.000 abstract 1
- 208000024172 Cardiovascular disease Diseases 0.000 abstract 1
- ZRALSGWEFCBTJO-UHFFFAOYSA-N Guanidine Chemical compound NC(N)=N ZRALSGWEFCBTJO-UHFFFAOYSA-N 0.000 abstract 1
- 229910018828 PO3H2 Inorganic materials 0.000 abstract 1
- 229910006069 SO3H Inorganic materials 0.000 abstract 1
- OMUIHEPWYQOQRW-UHFFFAOYSA-N aniline guanidine Chemical compound NC(=N)N.NC1=CC=CC=C1 OMUIHEPWYQOQRW-UHFFFAOYSA-N 0.000 abstract 1
- 235000012000 cholesterol Nutrition 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- QGBSISYHAICWAH-UHFFFAOYSA-N dicyandiamide Chemical compound NC(N)=NC#N QGBSISYHAICWAH-UHFFFAOYSA-N 0.000 abstract 1
- 230000000694 effects Effects 0.000 abstract 1
- 229960004198 guanidine Drugs 0.000 abstract 1
- 150000004702 methyl esters Chemical class 0.000 abstract 1
- 230000002265 prevention Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D257/00—Heterocyclic compounds containing rings having four nitrogen atoms as the only ring hetero atoms
- C07D257/02—Heterocyclic compounds containing rings having four nitrogen atoms as the only ring hetero atoms not condensed with other rings
- C07D257/04—Five-membered rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
- A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/404—Indoles, e.g. pindolol
- A61K31/405—Indole-alkanecarboxylic acids; Derivatives thereof, e.g. tryptophan, indomethacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C237/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups
- C07C237/02—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton
- C07C237/22—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton having nitrogen atoms of amino groups bound to the carbon skeleton of the acid part, further acylated
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C279/00—Derivatives of guanidine, i.e. compounds containing the group, the singly-bound nitrogen atoms not being part of nitro or nitroso groups
- C07C279/18—Derivatives of guanidine, i.e. compounds containing the group, the singly-bound nitrogen atoms not being part of nitro or nitroso groups having nitrogen atoms of guanidine groups bound to carbon atoms of six-membered aromatic rings
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Epidemiology (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Diabetes (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Vascular Medicine (AREA)
- Urology & Nephrology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Plant Substances (AREA)
- Indole Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US57822804P | 2004-06-09 | 2004-06-09 |
Publications (1)
Publication Number | Publication Date |
---|---|
PE20060102A1 true PE20060102A1 (es) | 2006-02-09 |
Family
ID=34978959
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PE2005000656A PE20060102A1 (es) | 2004-06-09 | 2005-06-09 | Pequenas moleculas para el tratamiento de hipercolesterolemia y enfermedades relacionadas |
Country Status (17)
Country | Link |
---|---|
US (1) | US20050277690A1 (zh) |
EP (1) | EP1753733A1 (zh) |
JP (1) | JP2008502737A (zh) |
KR (1) | KR20070043711A (zh) |
CN (1) | CN1964955A (zh) |
AR (1) | AR049217A1 (zh) |
AU (1) | AU2005255012A1 (zh) |
BR (1) | BRPI0511871A (zh) |
CA (1) | CA2568539A1 (zh) |
IL (1) | IL179209A0 (zh) |
MX (1) | MXJL06000070A (zh) |
NO (1) | NO20070141L (zh) |
PE (1) | PE20060102A1 (zh) |
RU (1) | RU2006146479A (zh) |
TW (1) | TW200603794A (zh) |
UY (1) | UY28951A1 (zh) |
WO (1) | WO2005123700A1 (zh) |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA2568543A1 (en) * | 2004-06-09 | 2005-12-29 | Avanir Pharmaceuticals | Mediators of reverse cholesterol transport for the treatment of hypercholesterolemia |
CN106916086A (zh) * | 2015-12-28 | 2017-07-04 | 深圳翰宇药业股份有限公司 | 一种对硝基苯胺修饰多肽c端的固相合成方法 |
Family Cites Families (18)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3930024A (en) * | 1969-09-02 | 1975-12-30 | Parke Davis & Co | Pharmaceutical compositions and methods |
US3773946A (en) * | 1969-09-02 | 1973-11-20 | Parke Davis & Co | Triglyceride-lowering compositions and methods |
US4448785A (en) * | 1978-01-09 | 1984-05-15 | Sandoz, Inc. | N-Unsaturated fatty acid amides of tryptophan ester homologues and anti-cholesteric use thereof |
JPS5522636A (en) * | 1978-08-04 | 1980-02-18 | Takeda Chem Ind Ltd | Thiazoliding derivative |
IL64542A0 (en) * | 1981-12-15 | 1982-03-31 | Yissum Res Dev Co | Long-chain alpha,omega-dicarboxylic acids and derivatives thereof and pharmaceutical compositions containing them |
JPS60136512A (ja) * | 1983-12-26 | 1985-07-20 | Eisai Co Ltd | 脂質代謝改善剤 |
US4643988A (en) * | 1984-05-15 | 1987-02-17 | Research Corporation | Amphipathic peptides |
DE3423166A1 (de) * | 1984-06-22 | 1986-01-02 | Epis S.A., Zug | Alpha-, omega-dicarbonsaeuren, verfahren zu ihrer herstellung und arzneimittel, die diese verbindungen enthalten |
US5648387A (en) * | 1995-03-24 | 1997-07-15 | Warner-Lambert Company | Carboxyalkylethers, formulations, and treatment of vascular diseases |
JPH10316641A (ja) * | 1997-03-14 | 1998-12-02 | Sankyo Co Ltd | カルボン酸誘導体 |
WO1999003880A1 (en) * | 1997-07-15 | 1999-01-28 | Novo Nordisk A/S | Nociceptin analogues |
US6004925A (en) * | 1997-09-29 | 1999-12-21 | J. L. Dasseux | Apolipoprotein A-I agonists and their use to treat dyslipidemic disorders |
US6410802B1 (en) * | 1999-04-01 | 2002-06-25 | Esperion Therapeutics, Inc. | Methods for synthesizing ether compounds and intermediates therefor |
US7148197B2 (en) * | 2000-08-24 | 2006-12-12 | The Regents Of The University Of California | Orally administered small peptides synergize statin activity |
US6664230B1 (en) * | 2000-08-24 | 2003-12-16 | The Regents Of The University Of California | Orally administered peptides to ameliorate atherosclerosis |
FR2820435B1 (fr) * | 2001-02-05 | 2004-02-27 | Genfit S A | Procedes d'identification de composes modulant le transport inverse du cholesterol |
US7429593B2 (en) * | 2001-09-14 | 2008-09-30 | Shionogi & Co., Ltd. | Utilities of amide compounds |
AU2004233333A1 (en) * | 2003-04-22 | 2004-11-04 | Avanir Pharmacueticals | Mediators of reverse cholesterol transport for the treatment of hypercholesterolemia |
-
2005
- 2005-06-09 MX MXJL06000070A patent/MXJL06000070A/es not_active Application Discontinuation
- 2005-06-09 BR BRPI0511871-9A patent/BRPI0511871A/pt not_active Application Discontinuation
- 2005-06-09 WO PCT/US2005/020661 patent/WO2005123700A1/en active Application Filing
- 2005-06-09 US US11/148,960 patent/US20050277690A1/en not_active Abandoned
- 2005-06-09 TW TW094119000A patent/TW200603794A/zh unknown
- 2005-06-09 RU RU2006146479/04A patent/RU2006146479A/ru not_active Application Discontinuation
- 2005-06-09 AU AU2005255012A patent/AU2005255012A1/en not_active Abandoned
- 2005-06-09 CA CA002568539A patent/CA2568539A1/en not_active Abandoned
- 2005-06-09 EP EP05758678A patent/EP1753733A1/en not_active Withdrawn
- 2005-06-09 UY UY28951A patent/UY28951A1/es not_active Application Discontinuation
- 2005-06-09 CN CNA2005800185810A patent/CN1964955A/zh active Pending
- 2005-06-09 AR ARP050102364A patent/AR049217A1/es unknown
- 2005-06-09 JP JP2007527788A patent/JP2008502737A/ja not_active Withdrawn
- 2005-06-09 PE PE2005000656A patent/PE20060102A1/es not_active Application Discontinuation
- 2005-06-09 KR KR1020067026457A patent/KR20070043711A/ko not_active Application Discontinuation
-
2006
- 2006-11-13 IL IL179209A patent/IL179209A0/en unknown
-
2007
- 2007-01-08 NO NO20070141A patent/NO20070141L/no not_active Application Discontinuation
Also Published As
Publication number | Publication date |
---|---|
US20050277690A1 (en) | 2005-12-15 |
CA2568539A1 (en) | 2005-12-29 |
NO20070141L (no) | 2007-03-02 |
UY28951A1 (es) | 2006-01-31 |
EP1753733A1 (en) | 2007-02-21 |
AR049217A1 (es) | 2006-07-05 |
BRPI0511871A (pt) | 2008-01-15 |
TW200603794A (en) | 2006-02-01 |
CN1964955A (zh) | 2007-05-16 |
IL179209A0 (en) | 2007-03-08 |
RU2006146479A (ru) | 2008-07-20 |
KR20070043711A (ko) | 2007-04-25 |
WO2005123700A1 (en) | 2005-12-29 |
AU2005255012A1 (en) | 2005-12-29 |
JP2008502737A (ja) | 2008-01-31 |
MXJL06000070A (es) | 2007-04-10 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CL2021001934A1 (es) | Compuestos de benzotiadiazepina y su uso como moduladores del ácido biliar. | |
PE20210182A1 (es) | Modificaciones de cristales de odexibat | |
PE20070849A1 (es) | Compuestos mimeticos de lisina modificados | |
DK1778720T3 (da) | Antimikrobielle peptider omfattende et arginin- og/eller lysinholdigt motiv | |
TW200833365A (en) | Neuronal exocytosis inhibiting peptides | |
EA023303B1 (ru) | Пептидная композиция для формирования толерантности к клещам домашней пыли и ее применение | |
CO6351742A2 (es) | Compuestos organicos para la cicatrizacion de heridas | |
ECSP056253A (es) | Composicion farmaceutica que contiene un inhibidor de histona desacetilasa | |
UY32083A (es) | Aminoidanos sustituidos y sus análogos, y el uso farmacéuticos de los mismos | |
DE60137932D1 (de) | Reduziertes fk228 und seine verwendung | |
ES2255467T1 (es) | Acidos grasos de cadena media, gliceridos y analogos como estimuladores de la eritropoyesis. | |
AR063942A1 (es) | Compuestos de oximilo aciclico inhibidores de proteasa del virus de hepatitis c | |
AR082444A1 (es) | Formulacion farmaceutica que comprende un inhibidor de fosfodiesterasa | |
PE20060102A1 (es) | Pequenas moleculas para el tratamiento de hipercolesterolemia y enfermedades relacionadas | |
CL2012002560A1 (es) | Metodos para el tratamiento de ulceras de pie diabetico que comprende un peptido de al menos 5 aminoacidos contiguos de nle3 a(1-7) efectivo; formulacion farmacéutica que comprende hidroxietil celulosa (hec) y un peptido de al menos 5 aminoacidos contiguos de nle3 a(1-7). | |
CO6280421A2 (es) | Bifosfatos de alquilo de 2 a 5 atomos de carbonoimidazol | |
BR112012015984A2 (pt) | composição para melhorar a função cerebral, e, polipeptídeo | |
BRPI0410419A (pt) | tratamento para a ansiedade com ziprasidona | |
UY33568A (es) | Compuestos que interactuan con proteina reguladora de glucocinasa para el tratamiento de diabetes. | |
DE602004024143D1 (de) | Verwendung von Fumarsäurederivaten zur Inhibition der PDGF-induzierten Thymidin-aufnahme bei glatten Bronchialmuskelzellen und zur Inhibition der Proliferation von glatten Bronchialmuskelzellen | |
RU2016112495A (ru) | Композиция для предотвращения или лечения атопического дерматита, содержащая моноацетилдиацилглицериновое соединение в качестве активного ингредиента | |
GT200600293A (es) | Mezclas fungicidas a base de bifenilamidas de ácido pirazolcarboxílico 3,5-disustituidas. | |
CO2023004112A2 (es) | Composiciones que contienen sales de ésteres de dialquil aminoácidos | |
Barone et al. | Effects of N-acetyl-L-cysteine on redox status and markers of renal function in mice inoculated with Bothrops jararaca and Crotalus durissus terrificus venoms | |
CO2021014899A2 (es) | Formulación para entrega oral de proteinas, peptidos y moleculas pequeñas con permeabilidad baja |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FA | Abandonment or withdrawal |